Article Information
History
- June 28, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Ewan Hunter1,
- Christina Koutsothanasi1,
- Adam Wilson1,
- Francisco C. Santos1,
- Matthew Salter1,
- Jurjen W. Westra1,
- Ryan Powell1,
- Ann Dring1,
- Paulina Brajer1,
- Benedict Egan1,
- Matthew Parnall1,
- Catriona Williams1,
- Aemilia Katzinski1,
- Thomas Lavin1,
- Aroul Ramadass1,
- William Messer2,
- Amanda Brunton2,
- Zoe Lyski2,
- Rama Vancheeswaran3,
- Andrew Barlow3,
- Dmitri Pchejetski4,
- Peter A. Robbins5,7,
- Jane Mellor6,7 and
- Alexandre Akoulitchev1,*
- 1Oxford BioDynamics Plc, Oxford UK
- 2Oregon Health & Science University, Portland, OR
- 3West Hertfordshire NHS Trust, Watford, UK
- 4Norwich Medical School, University of East Anglia
- 5Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
- 6Department of Biochemistry, University of Oxford, Oxford, UK
- 7The Queen’s College, University of Oxford, Oxford, UK
- ↵*Address correspondence to: alexandre.akoulitchev{at}oxfordbiodynamics.com
Posted June 28, 2021.
Development and validation of blood-based prognostic biomarkers for severity of COVID disease outcome using EpiSwitch 3D genomic regulatory immuno-genetic profiling
